Pharmacologically active microcarriers influence VEGF-A effects on mesenchymal stem cell survival

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 1, 2013, Pages 192-204

  Penna, Claudia ^a,e   Perrelli, Maria Giulia ^a,e   Karam, Jean Pierre ^c,d   Angotti, Carmelina ^a,e   Muscari, Claudio ^b,e   Montero Menei, Claudia N ^b,c   Pagliaro, Pasquale ^a,e  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c LUNAM Universite   (France)

^d UNIVERSITÉ D'ANGERS   (France)

^e National Institute for Cardiovascular Research   (Italy)

Author keywords

Drug release; Growth factor; Hypoxia; Microspheres; Stem cells; Transplantation

Indexed keywords

CASPASE 3; DRUG CARRIER; LACTIC ACID; MAPK1 PROTEIN, HUMAN; MICROSPHERE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXYGEN; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; PROTEIN KINASE B; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANIMAL; ARTICLE; CELL HYPOXIA; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DRUG EFFECT; DRUG FORMULATION; GENETICS; KINETICS; MESENCHYMAL STROMA CELL; METABOLISM; PRIMARY CELL CULTURE; RAT; WISTAR RAT;

ANIMALS; CASPASE 3; CELL HYPOXIA; CELL SURVIVAL; DRUG CARRIERS; DRUG COMPOUNDING; KINETICS; LACTIC ACID; MESENCHYMAL STROMAL CELLS; MICROSPHERES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OXYGEN; POLYGLYCOLIC ACID; PRIMARY CELL CULTURE; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84873148798     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01662.x     Document Type: Article

References (61)

1. Marbán E, Cheng K. Heart to heart: the elusive mechanism of cell therapy. Circulation. 2010; 121: 1981-4.
2. Wen Z, Zheng S, Zhou C, et al. Repair mechanisms of bone marrow mesenchymal stem cells in myocardial infarction. J Cell Mol Med. 2011; 15: 1032-43.
3. Passier R, van Laake LW, Mummery CL. Stem-cell-based therapy and lessons from the heart. Nature. 2008; 453: 322-9.
4. Segers VFM, Lee RT. Stem cell-therapy for cardiac disease. Nature. 2008; 451: 937-42.
5. Wang JA, Chen TL, Jiang J, et al. Hypoxic preconditioning attenuates hypoxia/reoxygenation-induced apoptosis in mesenchymal stem cells. Acta Pharmacol Sin. 2008; 29: 74-82.
6. Song H, Song BW, Cha MJ, et al. Modification of mesenchymal stem cells for cardiac regeneration. Expert Opin Biol Ther. 2010 Mar; 10(3): 309-19.
7. Toma C, Pittenger MF, Cahill KS, et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002; 105: 93-8.
8. Boudoulas KD, Hatzopoulos AK. Cardiac repair and regeneration: the Rubik's cube of cell therapy for heart disease. Dis Model Mech. 2009; 2: 344-58.
9. Ohishi M, Schipani E. Bone marrow mesenchymal stem cells. J Cell Biochem. 2010; 109: 277-82.
10. Terada N, Hamazaki T, Oka M, et al. Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature. 2002; 416: 542-5.
11. Ying QL, Nichols J, Evans EP, et al. Changing potency by spontaneous fusion. Nature. 2002; 416: 545-8.
12. Vassilopoulos G, Russell DW. Cell fusion: an alternative to stem cell plasticity and its therapeutic implications. Curr Opin Genet Dev. 2003; 13: 480-5.
13. Spees JL, Olson SD, Ylostalo J, et al. Differentiation, cell fusion, and nuclear fusion during ex vivo repair of epithelium by human adult stem cells from bone marrow stroma. Proc Natl Acad Sci USA. 2003; 100: 2397-402.
14. Nygren JM, Jovinge S, Breitbach M, et al. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med. 2004; 10: 494-501.
15. Alvarez-Dolado M, Pardal R, Garcia-Verdugo JM, et al. Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature. 2003; 425: 968-73.
16. Oh H, Bradfute SB, Gallardo TD, et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci USA. 2003; 100: 12313-8.
17. Shi D, Reinecke H, Murry CE, et al. Myogenic fusion of human bone marrow stromal cells, but not hematopoietic cells. Blood. 2004; 104: 290-4.
18. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res. 2001; 49: 568-81.
19. Mandriota SJ, Pepper MS. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J Cell Sci. 1997; 110: 2293-302.
20. Hiasa K, Egashira K, Kitamoto S, et al. Bone marrow mononuclear cell therapy limits myocardial infarct size through vascular endothelial growth factor. Basic Res Cardiol. 2004; 99: 165-72.
21. Tang YL, Zhao Q, Zhang YC, et al. Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul Pept. 2004; 117: 3-10.
22. Beckermann BM, Kallifatidis G, Groth A, et al. VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer. 2008; 99: 622-31.
23. Guzman MJ, Crisostomo PR, Wang M, et al. Vascular endothelial growth factor improves myocardial functional recovery following ischemia/reperfusion injury. J Surg Res. 2008; 150: 286-92.
24. Cross MJ, Dixelius J, Matsumoto T, et al. VEGF receptor signal transduction. Trends Biochem Sci. 2003; 28: 488-94.
25. Hoeben A, Landuyt B, Highley MS, et al. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004; 56: 549-80.
26. Alenzi FQ, Alenazi BQ, Ahmad SY, et al. The haemopoietic stem cell: between apoptosis and self renewal. Yale J Biol Med. 2009; 82: 7-18.
27. Delcroix GJ, Schiller PC, Benoit JP, et al. Adult cell therapy for brain neuronal damages and the role of tissue engineering. Biomaterials. 2010; 31: 2105-20.
28. Delcroix GJ, Garbayo E, Sindji L, et al. The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemi-parkinsonian rats. Biomaterials. 2011; 32: 1560-73.
29. Elçin YM, Dixit V, Gitnick G. Extensive in vivo angiogenesis following controlled release of human vascular endothelial cell growth factor: implications for tissue engineering and wound healing. Artif Organs. 2001; 25: 558-65.
30. Giteau A, Venier-Julienne MC, Marchal S, et al. Reversible protein precipitation toward its stabilization during encapsulation and release from PLGA microspheres. Eur J Pharm Biopharm. 2008; 70: 127-36.
31. Bouffi C, Thomas O, Bony C, et al. The role of pharmacologically active microcarriers releasing TGF-beta3 in cartilage formation in vivo by mesenchymal stem cells. Biomaterials. 2010; 31: 6485-93.
32. Muscari C, Bonafé F, Stanic I, et al. Polyamine depletion reduces TNFalpha/MG132-induced apoptosis in bone marrow stromal cells. Stem Cells. 2005; 23: 983-91.
33. Gallo MP, Ramella R, Alloatti G, et al. Limited plasticity of mesenchymal stem cells cocultured with adult cardiomyocytes. J Cell Biochem. 2007; 100: 86-99.
34. Raimondo S, Penna C, Pagliaro P, et al. Morphological characterization of GFP stably transfected adult mesenchymal bone marrow stem cells. J Anat. 2006; 208: 3-12.
35. Penna C, Raimondo S, Ronchi G, et al. Early homing of adult mesenchymal stem cells in normal and infarcted isolated beating hearts. J Cell Mol Med. 2008; 12: 507-21.
36. Wang X, Willenbring H, Akkari Y, et al. Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature. 2003; 422: 897-901.
37. Penna C, Cappello S, Mancardi D, et al. Post-conditioning reduces infarct size in the isolated rat heart: role of coronary flow and pressure and the nitric oxide/cGMP pathway. Basic Res Cardiol. 2006; 101: 168-79.
38. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72: 248-54.
39. Penna C, Perrelli MG, Raimondo S, et al. Postconditioning induces an anti-apoptotic effect and preserves mitochondrial integrity in isolated rat hearts. Biochim Biophys Acta. 2009; 1787: 794-801.
40. Rosenstein JM, Mani N, Silverman WF, et al. Patterns of brain angiogenesis after vascular endothelial growth factor administration in vitro and in vivo. Proc Natl Acad Sci U S A. 1998; 95: 7086-91.
41. Ball SG, Shuttleworth CA, Kielty CM. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol. 2007; 177: 489-500.
42. Rodríguez-Juan C, de la Torre P, García-Ruiz I, et al. Fibronectin increases survival of rat hepatic stellate cells-a novel profibrogenic mechanism of fibronectin. Cell Physiol Biochem. 2009; 24: 271-82.
43. Crow MT, Mani K, Nam YJ, et al. The mitochondrial death pathway and cardiac myocyte apoptosis. Circ Res. 2004; 95: 957-70.
44. Saleh FA, Whyte M, Ashton P, et al. Regulation of mesenchymal stem cell activity by endothelial cells. Stem Cells Dev. 2011; 20: 391-403.
45. Zhang B, Yang S, Zhang Y, et al. Co-culture of mesenchymal stem cells with umbilical vein endothelial cells under hypoxic condition. J Huazhong Univ Sci Technolog Med Sci. 2012; 32: 173-80.
46. Lee WY, Wei HJ, Wang JJ, et al. Vascularization and restoration of heart function in rat myocardial infarction using transplantation of human cbMSC/HUVEC core-shell bodies. Biomaterials. 2012; 33: 2127-36.
47. Steiner D, Lampert F, Stark GB, et al. Effects of endothelial cells on proliferation and survival of human mesenchymal stem cells and primary osteoblasts. J Orthop Res. 2012; 30: 1682-9.
48. Lee WY, Tsai HW, Chiang JH, et al. Core-shell cell bodies composed of human cbMSCs and HUVECs for functional vasculogenesis. Biomaterials. 2011; 32: 8446-55.
49. Hung SC, Pochampally RR, Chen SC, et al. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells. 2007; 25: 2363-70.
50. Gaebel R, Ma N, Liu J, et al. Patterning human stem cells and endothelial cells with laser printing for cardiac regeneration. Biomaterials. 2011; 32: 9218-30.
51. Markel TA, Wang Y, Herrmann JL, et al. VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function. Am J Physiol Heart Circ Physiol. 2008; 295: H2308-14.
52. Deuse T, Peter C, Fedak PW, et al. Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation 2009; 120(11 Suppl.): S247-54.
53. Tatard VM, Menei P, Benoit JP, et al. Combining polymeric devices and stem cells for the treatment of neurological disorders: a promising therapeutic approach. Curr Drug Targets. 2005; 6: 81-96.
54. Michel JB. Anoikis in the cardiovascular system: known and unknown extracellular mediators. Arterioscler Thromb Vasc Biol. 2003; 23: 2146-54.
55. Meirelles Lda S, Fontes AM, Covas DT, et al. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 2009; 20: 419-27.
56. Das R, Jahr H, van Osch GJ, et al. The role of hypoxia in bone marrow-derived mesenchymal stem cells: considerations for regenerative medicine approaches. Tissue Eng Part B Rev. 2010; 16: 159-68.
57. Pasumarthi KB, Field LJ. Cardiomyocyte cell cycle regulation. Circ Res. 2002; 90: 1044-54.
58. Makino S, Fukuda K, Miyoshi S, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest. 1999; 103: 697-705.
59. Kawada H, Fujita J, Kinjo K, et al. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood. 2004; 104: 3581-7.
60. Musilli C, Karam JP, Paccosi S, et al. Pharmacologically active microcarriers for endothelial progenitor cell support and survival. Eur J Pharm Biopharm. 2012; 81: 609-16.
61. Menei P, Montero-Menei C, Venier MC, et al. Drug delivery into the brain using poly(lactide-co-glycolide) microspheres. Expert Opin Drug Deliv. 2005; 2: 363-76.